Literature DB >> 17828420

Screening and detection of portal vein tumor thrombi-associated serum low molecular weight protein biomarkers in human hepatocellular carcinoma.

Ji-Gang Qiu1, Jia Fan, Yin-Kun Liu, Jian Zhou, Zhi Dai, Cheng Huang, Zhao-You Tang.   

Abstract

PURPOSE: Serum low molecular weight protein biomarkers might be important in relation to portal vein tumor thrombi (PVTT) in hepatocellular carcinoma (HCC). This study aimed to screen and to detect these biomarkers.
METHODS: We selected sera of 3 groups from 12 healthy volunteers, 12 HCC patients without PVTT and 12 HCC patients with PVTT, respectively. By using two-dimensional gel electrophoresis (2-DE) in which the first dimension was 16% SDS-PAGE, serum protein images of 3 groups were analyzed by Image Master Software. The differential protein spots were further identified by MALDI-TOF MS/MS.
RESULTS: Compared with 12.5% SDS-PAGE gel, there were more protein bands between 3 and 20 kDa in 16% SDS-PAGE gel and low molecular weight (MW) protein spots (< 20 kDa) were clearly shown. Fifteen differential protein spots representing five proteins were found in the three groups by inter-class comparison and were then identified. Compared with the healthy group, apolipoprotein A-I, lipoprotein CIII, transthyretin and DNA topoisomerase II were down regulated in HCC groups while haptoglobin-2 was over expressed. All the five proteins were less in PVTT group than in non-PVTT group.
CONCLUSION: The expression of low MW serum protein changes obviously in the beginning and progressive stage of HCC, and differentially expressed low MW proteins might be the potential biomarkers in early prognostication and surveillance of treatment for HCC and PVTT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828420     DOI: 10.1007/s00432-007-0236-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  20 in total

Review 1.  The current state of two-dimensional electrophoresis with immobilized pH gradients.

Authors:  A Görg; C Obermaier; G Boguth; A Harder; B Scheibe; R Wildgruber; W Weiss
Journal:  Electrophoresis       Date:  2000-04       Impact factor: 3.535

2.  [The effects of portal vein microscopic and macroscopic tumor thrombi on post-operation patients with hepatocellular carcinoma].

Authors:  Jia Fan; Zhao-you Tang; Zhi-quan Wu; Jian Zhou; Xin-da Zhou; Zeng-chen Ma; Lun-xiu Qin; Shuang-jian Qiu; Yao Yu; Cheng Huang
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2005-04-01

Review 3.  Hepatocellular carcinoma surgery--review of the past and prospects for the 21st century.

Authors:  Zhao-You Tang
Journal:  J Surg Oncol       Date:  2005-08-01       Impact factor: 3.454

4.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.

Authors:  H Schägger; G von Jagow
Journal:  Anal Biochem       Date:  1987-11-01       Impact factor: 3.365

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  A single bifunctional enzyme, PilD, catalyzes cleavage and N-methylation of proteins belonging to the type IV pilin family.

Authors:  M S Strom; D N Nunn; S Lory
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

7.  Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis.

Authors:  Ju-Tao Feng; Yin-Kun Liu; Hai-Yan Song; Zhi Dai; Lun-Xiu Qin; Mohamad Radwan Almofti; Cai-Yun Fang; Hao-Jie Lu; Peng-Yuan Yang; Zhao-You Tang
Journal:  Proteomics       Date:  2005-11       Impact factor: 3.984

Review 8.  Practice guidelines for tumor marker use in the clinic.

Authors:  Catharine Sturgeon
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

9.  Serum apolipoproteins A-I, A-II and B in hepatic metastases. Comparison with other liver diseases: hepatomas and cirrhosis.

Authors:  H Hachem; G Favre; G Raynal; G Blavy; P Canal; G Soula
Journal:  J Clin Chem Clin Biochem       Date:  1986-03

10.  Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer.

Authors:  N Ahmed; G Barker; K T Oliva; P Hoffmann; C Riley; S Reeve; A I Smith; B E Kemp; M A Quinn; G E Rice
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

View more
  5 in total

1.  Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma.

Authors:  T Wang; H S Hu; Y X Feng; J Shi; N Li; W X Guo; J Xue; D Xie; S R Liu; M C Wu; S Q Cheng
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

2.  Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma.

Authors:  Ju-Xian Sun; Jie Shi; Nan Li; Wei-Xing Guo; Meng-Chao Wu; Wan-Yee Lau; Shu-Qun Cheng
Journal:  Cancer Biol Med       Date:  2016-12       Impact factor: 4.248

3.  DEIsoM: a hierarchical Bayesian model for identifying differentially expressed isoforms using biological replicates.

Authors:  Hao Peng; Yifan Yang; Shandian Zhe; Jian Wang; Michael Gribskov; Yuan Qi
Journal:  Bioinformatics       Date:  2017-10-01       Impact factor: 6.937

4.  Serum Glycoprotein Markers in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.

Authors:  Prasanna Ramachandran; Gege Xu; Hector H Huang; Rachel Rice; Bo Zhou; Klaus Lindpaintner; Daniel Serie
Journal:  J Proteome Res       Date:  2022-03-14       Impact factor: 4.466

5.  Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations.

Authors:  Haddy K S Fye; Cynthia Wright-Drakesmith; Holger B Kramer; Suzi Camey; Andre Nogueira da Costa; Adam Jeng; Alasana Bah; Gregory D Kirk; Mohamed I F Sharif; Nimzing G Ladep; Edith Okeke; Pierre Hainaut; Simon D Taylor-Robinson; Benedikt M Kessler; Maimuna E Mendy
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.